In Japan, policymakers and providers face a difficult challenge in weighing the costs and benefits of various medical technologies to decide how best to use and invest in medical devices and diagnostics in the country’s highly stretched healthcare system.
In this report sponsored by Advamed, EIU explores the economic impact of screening and treatment using medical technology in Japan. The study was built on a model of four diseases with a large impact on the population (cerebrovascular disease, lung cancer, diabetes and musculoskeletal disorders) and eight medical devices.
- MedTech interventions for screening and treatment provide overall net savings to Japan despite their high up-front costs
- Net savings per patient ranges from US$385 in early detection of lung cancer to US$28,071 for hip replacement patients, in cases explored
Download report (English) 医療技術と